An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          Grants & Funding: The NIAMS Extramural Program
          Clinical Trials in the Spotlight
          Photodynamic Therapy-Induced Immune Modulation: Part III








Photodynamic Therapy-Induced Immune Modulation: Part III FacebookEmailPrintFacebookEmail     
    Clinical Trials in the Spotlight Main Page

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal, and skin diseases.  Investigators supported by the NIAMS need your help finding individuals to participate in clinical trials.  Participating in clinical trials allows you to play an active role as a volunteer in research and contribute to generating new knowledge about the disease/condition, and potentially future treatments.  The information below is designed to help you quickly learn about actively recruiting research studies for which you or someone you know may be eligible.

Study Description

Numerous environmental and iatrogenic pro-oxidative stressors ranging from chemotherapy to ultraviolet radiation have been demonstrated to induce immunosuppression in preclinical murine (mouse) models. These stressors have also been shown to be potent inducers of the lipid mediator platelet-activating factor (PAF), which exerts immunosuppressive effects in murine models. The previous work has characterized the exact pathways by which PAF-dependent immunosuppression occurs and have identified a major role of regulatory T cells (Treg). PAF released from injury acts upon the mast cell PAF receptor resulting in the formation of immunosuppressive Tregs. This process is dependent upon the cytokine IL-10 and cyclooxygenase-2 (COX-2) generated prostaglandins. Though high levels of PAF has been shown to be generated in humans in response to many of the immunosuppressive stressors that induce PAF in animal models, studies are needed to define if this PAF COX-2Treg pathway is functional in humans.

The study team has found that topical photodynamic therapy (PDT) is a very potent inducer of PAF in murine skin, and induces systemic immunosuppression only in mice expressing PAF receptors. Therefore, this study is designed to test if the PAF COX-2 Treg pathway is involved in PDT-induced effects and could be pharmacologically modulated with COX-2 inhibitors to block the immunosuppression and potentially improve PDT efficacy in treating precancerous actinic keratoses lesions.

The study will test if standard PDT performed in dermatology clinics generates: 1) PAF and related oxidized glycerophosphocholines in skin; 2) systemic isoprostanes in response to reactive oxygen species; and 3) systemic COX-produced prostaglandins. The study team will also characterize the immunosuppressive effects of PDT in humans by both skin testing, and assaying Tregs and T cell responses against established and neo-antigens. The ability of short-term post-PDT treatment with the COX-2 inhibitor celecoxib to modulate PDT-mediated immunosuppression and clinical effectiveness will also be defined. These translational studies will thus define if a previously unappreciated immunomodulatory pathway is engaged following PDT which can be exploited to enhance treatment outcomes. If successful, these studies will change the standard of care for how PDT is administered.

**ELIGIBILITY CRITERIA:**

Ages Eligible for Study:           45 Years and older   (Adult, Older Adult)

Sexes Eligible for Study:          All

Accepts Healthy Volunteers:  Yes

**Inclusion Criteria:**

Inclusion Criteria for Control Subjects:

Adult age 45 or older
	Caucasian (Fair skin, Fitzpatrick types I and II)
	Ability to understand and consent to the instructions of the study
	Have access to stable transportationInclusion Criteria for Study Subjects:

Wright State University dermatologist has prescribed PDT for the treatment of actinic damage (Presence of precancerous actinic keratoses whose treatment necessitates PDT with the BLU-U).
	Undergoing PDT on greater than 5% body surface area: face and scalp, face and dorsal surface of arms, face and chest, face and back, or dorsal surface of arms alone, chest alone, or back alone.
	Caucasian (Fair skin, Fitzpatrick types I and II)
	Adult-age 45 or older
	Ability to understand the informed consent and comply with instructions and have stable transportation.**Exclusion Criteria:**

PDT on less than 5% body surface area (eg, forehead)
	Present treatment with corticosteroids or Non-steroidal inflammatory drugs (e.g., cyclooxygenase inhibitors) within past 2 months (except low-dose 81 mg aspirin).
	On antioxidant supplements (e.g., vitamin C) for past 2 months
	Tanning bed use within last 3 months
	PDT treatments within last 3 months
	Significant health issues that could affect the immune system (e.g., uncontrolled Diabetes Mellitus, Rheumatoid arthritis, skin rashes, psoriasis) that could interfere with testing
	Pregnant or nursing
	No immunosuppression, and on no immunosuppressive medications or NSAIDS within past 30 days (except low-dose [81 mg daily] aspirin).
	No significant underlying diseases that could potentially interfere with the immune assays or cardiac or renal or liver problems.
	History of blood clot or hypercoagulable state or GI bleed/ulceration.**Study Design:**

Allocation: Randomized

Intervention Model: Parallel Assignment

Masking:Double (Participant, Investigator)

Primary Purpose: Prevention

**Study Location(s):**

Wright State University, Dayton, Ohio, United States, 45435

**Study Website:**

https://clinicaltrials.gov/ct2/show/NCT03643744?term=NCT03643744&rank=1


Last Updated: August 2019


Back to Top
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy